Loading…
PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction
Lombardi, Giuseppe, Spimpolo, Alessandro, Berti, Sara, Campi, Cristina, Anglani, Maria Giulia, Simeone, Rossella, Evangelista, Laura, Causin, Francesco, Zorzi, Giovanni, Gorgoni, Giancarlo, Caccese, Mario, Padovan, Marta, Zagonel, Vittorina, Cecchin, Diego
Published in British journal of radiology (01.01.2022)
Published in British journal of radiology (01.01.2022)
Get full text
Journal Article
Loading…
Loading…
Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects
Gerisch, Michael, Hafner, Frank-Thorsten, Lang, Dieter, Radtke, Martin, Diefenbach, Konstanze, Cleton, Adriaan, Lettieri, John
Published in Cancer chemotherapy and pharmacology (01.01.2018)
Published in Cancer chemotherapy and pharmacology (01.01.2018)
Get full text
Journal Article
Loading…
Loading…
Analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) and Child-Pugh (CP)-B liver function treated with regorafenib in routine clinical practice in the observational REFINE study
Merle, Philippe, Finn, Richard S., Kudo, Masatoshi, Klümpen, Heinz-Josef, Lim, Ho Yeong, Pinter, Matthias, Babajanyan, Svetlana, Khan, Javeed, Awan, Maria, Özgürdal, Kirhan, Qin, Shukui
Published in Journal of clinical oncology (20.01.2024)
Published in Journal of clinical oncology (20.01.2024)
Get full text
Journal Article
Loading…
A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy
Shiri, Pezhman, Ramezanpour, Sorour, Amani, Ali Mohammad, Dehaen, Wim
Published in Molecular diversity (01.10.2022)
Published in Molecular diversity (01.10.2022)
Get full text
Journal Article
Loading…
A randomized, open-label, two-period crossover study to evaluate the bioequivalence and food effect between two formulations of regorafenib in healthy adult participants
Li, Yan, Qi, Lu, Yang, Caixia, Zhao, Na, Wang, Xinghe
Published in Frontiers in pharmacology (19.03.2025)
Published in Frontiers in pharmacology (19.03.2025)
Get full text
Journal Article
Loading…
Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers
Zimmermann, Torsten, Höchel, Joachim, Becka, Michael, Boettger, Michael K., Rohde, Beate, Schug, Barbara, Kunert, Kathleen S., Donath, Frank
Published in British journal of clinical pharmacology (01.05.2018)
Published in British journal of clinical pharmacology (01.05.2018)
Get full text
Journal Article
Loading…
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy
Petrioli, Roberto, Chirra, Martina, Messuti, Luciana, Fiaschi, Anna Ida, Savelli, Vinno, Martellucci, Ignazio, Francini, Edoardo
Published in Clinical colorectal cancer (01.12.2018)
Published in Clinical colorectal cancer (01.12.2018)
Get full text
Journal Article
Loading…
A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study
Riedel, Richard F., Ballman, Karla V., Lu, Yao, Attia, Steven, Loggers, Elizabeth T., Ganjoo, Kristen N., Livingston, Michael B., Chow, Warren, Wright, Jennifer, Ward, John H., Rushing, Daniel, Okuno, Scott H., Reed, Damon R., Liebner, David A., Keedy, Vicki L., Mascarenhas, Leo, Davis, Lara E., Ryan, Christopher, Reinke, Denise K., Maki, Robert G.
Published in The oncologist (Dayton, Ohio) (01.11.2020)
Published in The oncologist (Dayton, Ohio) (01.11.2020)
Get full text
Journal Article
Loading…
Loading…
Loading…
Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial
Zittel, Jason, Baran, Andrea M., Dotan, Efrat, Hubbard, Joleen M., Noel, Marcus Smith, Hezel, Aram F, Tejani, Mohamedtaki Abdulaziz, Mohile, Supriya Gupta
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Loading…
Bacteremic pneumonia caused by Enterococcus hirae in a subject receiving regorafenib
Merlo, Javier, Bustamante, Gloria, Llibre, Josep M.
Published in Enfermedades infecciosas y microbiologia clinica (01.05.2020)
Published in Enfermedades infecciosas y microbiologia clinica (01.05.2020)
Get full text
Journal Article
Loading…
A phase II clinical evaluation of radiofrequency ablation (RFA) combined with regorafenib and toripalimab in patients with colorectal cancer with liver metastases
Ouyang, Hui, Luo, Huiyan, Gao, Fei, Mie, Man, Ren, Chao, Li, Ji-Bin, Fu, Haiyan, Huang, Jin Shan
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Loading…
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
Clarke, Jeffrey Melson, Blobe, Gerard C., Strickler, John H., Uronis, Hope Elizabeth, Zafar, S. Yousuf, Morse, Michael, Dropkin, Evan, Howard, Leigh, O’Neill, Margot, Rushing, Christel N., Niedzwiecki, Donna, Watson, Hollie, Bolch, Emily, Arrowood, Christy, Liu, Yingmiao, Nixon, Andrew B., Hurwitz, Herbert I.
Published in Cancer chemotherapy and pharmacology (01.10.2019)
Published in Cancer chemotherapy and pharmacology (01.10.2019)
Get full text
Journal Article
Loading…
Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro
Dituri, Francesco, Scialpi, Rosanna, Schmidt, Tannin A., Frusciante, Martina, Mancarella, Serena, Lupo, Luigi Giovanni, Villa, Erica, Giannelli, Gianluigi
Published in Cell death & disease (16.11.2020)
Published in Cell death & disease (16.11.2020)
Get full text
Journal Article
Loading…
COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials
Rethouze, F., Risbourg, S., Schiffler, C., Chabaud, S., de Courrèges, A., Le Deley, M.-C., Blay, J.Y., Feutry, F., Jimenez, M., Vanseymortier, M., Penel, N., Duffaud, F., Lebellec, L.
Published in ESMO open (01.06.2025)
Published in ESMO open (01.06.2025)
Get full text
Journal Article
Loading…
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer
Oshima, Kotoe, Hirano, Hidekazu, Shoji, Hirokazu, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Boku, Narikazu
Published in PloS one (02.06.2022)
Published in PloS one (02.06.2022)
Get full text
Journal Article
Loading…
Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study)
Ishiyama, Shun, Yamada, Takeshi, Nakamura, Masato, Enomoto, Masanobu, Sugimoto, Kiichi, Yokomizo, Hajime, Kosugi, Chihiro, Ohta, Ryo, Ishimaru, Kei, Sonoda, Hiromichi, Ishibashi, Keiichiro, Kuramochi, Hidekazu, Yoshida, Yoichiro, Ichikawa, Daisuke, Hirata, Keiji, Yoshida, Hiroshi, Hashiguchi, Yojiro, Ishida, Hideyuki, Koda, Keiji, Katsumata, Kenji, Sakamoto, Kazuhiro
Published in International journal of clinical oncology (01.08.2022)
Published in International journal of clinical oncology (01.08.2022)
Get full text
Journal Article